Natera, Inc. (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, has reported a recent transaction by Chief Financial Officer Michael Burkes Brophy. According to the latest filings, Brophy exercised options and subsequently sold a portion of the company's common stock, resulting in a total sale of over $82,000.
The transactions, which took place on March 27th and 28th, involved the acquisition and disposal of shares through the exercise of options and stock sales. On March 27th, Brophy exercised options to acquire 2,292 shares of Natera's common stock. The following day, he sold 914 shares at an average price of $90.4158 per share. This sale amounted to a total value of approximately $82,640.
The sale was conducted in part to satisfy tax withholding and remittance obligations associated with the vesting of Restricted Stock Units (RSUs), as indicated by a footnote in the filing. The RSUs were part of a grant made on March 27, 2020, which vests over four years, with 25% vested on March 27, 2021, and the remainder vesting in equal quarterly installments thereafter.
Investors and market watchers often pay close attention to insider transactions as they can provide insights into executives' perspectives on the company's stock value. Following the transaction, Brophy's direct ownership in the company stands at 72,024 shares of common stock.
Natera has been at the forefront of genetic testing, providing services that range from prenatal screenings to cancer diagnostics. The company's stock performance is closely monitored by investors interested in the healthcare and biotechnology sectors.
The transactions were filed with the Securities and Exchange Commission and are publicly accessible for review. Natera's stock continues to be watched by investors who consider insider trading activity alongside other factors when evaluating their investment decisions.
InvestingPro Insights
Natera, Inc. (NASDAQ:NTRA) has been making waves in the personalized genetic testing industry, and recent insider transactions have put the spotlight on the company's financial health and stock performance. Here are some key insights based on real-time data from InvestingPro and InvestingPro Tips that investors may find valuable:
InvestingPro Data:
- Market Cap: $11.04B
- Revenue Growth (Last twelve months as of Q4 2023): 31.99%
- Price / Book (Last twelve months as of Q4 2023): 14.43
InvestingPro Tips:
- Analysts have recently revised their earnings expectations upwards for the upcoming period, indicating potential optimism about the company's future performance.
- Despite not being profitable over the last twelve months, Natera's liquid assets exceed its short-term obligations, suggesting financial stability in the near term.
Investors considering Natera's stock may be encouraged by the company's strong revenue growth and the positive revisions in earnings forecasts. Additionally, the company's healthy liquidity position could provide some assurance against market volatility. However, the lack of profitability and the high Price / Book multiple may warrant a closer look at the company's valuation.
For those looking to delve deeper into Natera's financials and stock performance, InvestingPro offers additional insights and metrics. There are a total of 13 InvestingPro Tips available for Natera, which can provide more comprehensive analysis for investors. To access these tips and benefit from the full suite of features, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.